Corvus Pharmaceuticals Conference Call Summary Company Overview - **Company**: Corvus Pharmaceuticals (NasdaqGM:CRVS) - **Date**: January 20, 2026 - **Key Executives Present**: Dr. Richard Miller (CEO), Leif Lea (CFO), Jeff Arcara (CBO), Dr. Ben Jones (SVP, Pharmaceutical Development), Dr. Suresh Mahabhashyam (VP, Clinical Development) [2][3] Core Industry and Product Focus - **Industry**: Pharmaceuticals, specifically focusing on immune diseases and atopic dermatitis - **Product**: Socalitinib, a first-in-class oral drug targeting interleukin-2 inducible T-cell kinase (ITK) [4][39] Key Findings and Data from Clinical Trials - **Phase I Clinical Trial Results**: - Socalitinib shows potential as a leading therapy for atopic dermatitis, achieving significant clinical results [5][6] - Efficacy metrics: - EASI 75: 75% of patients - EASI 90: 25% of patients - IGA 0/1: 33% of patients - Mean percent reduction in EASI score: 72% at eight weeks [6][24] - Responses are durable, with continued reduction in EASI scores post-treatment [6][21] - **Cohort 4 Specifics**: - 24 patients enrolled with a one-to-one randomization of active versus placebo - Treatment duration extended to eight weeks, confirming positive results from earlier cohorts [18][24] - EASI score reduction: 72% for Socalitinib vs. 40% for placebo, p-value of 0.035 [24][26] - **Prior Systemic Therapy**: - 35% of all patients had prior therapies, with 50% in cohort 4 - Socalitinib demonstrated efficacy in patients with prior systemic therapy, indicating no resistance [27][30] Mechanism of Action - Socalitinib selectively inhibits ITK, leading to a rebalancing of the immune system without causing immunosuppression [9][10] - Induction of T regulatory cells (Tregs) contributes to durable suppression of inflammation [21][30] Market Opportunity - Over 3 million patients with moderate to severe atopic dermatitis, with a significant unmet need for safe and effective oral therapies [15][38] - The market for atopic dermatitis is projected to grow to $170 billion by 2030, with oral agents expected to gain a larger share [38] Future Plans - Initiation of a phase 2 randomized placebo-controlled trial in atopic dermatitis, planned to enroll 200 patients [37][39] - Exploration of Socalitinib's efficacy in other immune diseases, including hidradenitis suppurativa and asthma [39] Safety Profile - No new safety signals observed in cohort 4; adverse events (AEs) were similar between active and placebo groups [31][55] - Historical data from lymphoma studies indicate a strong safety profile, with no patients discontinuing due to safety concerns [54][55] Conclusion - Socalitinib is positioned as a promising treatment for atopic dermatitis and potentially other immune diseases, with a strong clinical efficacy and safety profile [39][40]

Core Insights - Nurix Therapeutics (NRIX) is positioned to make significant advancements in the treatment of Chronic Lymphocytic Leukemia (CLL) and immune diseases, indicating a potential shift in therapeutic approaches within this market [1] Industry Overview - The CLL treatment market has been predominantly controlled by BTK inhibitors, specifically Ibrutinib and Pirtobrutinib, highlighting the competitive landscape and the challenges faced by new entrants [1]

Core Insights - AbbVie is showcasing significant advancements in its oncology portfolio at the upcoming ASCO Annual Meeting, highlighting investigational antibody-drug conjugates (ADCs) targeting various difficult-to-treat cancers [2][3]. Group 1: Key Data Presentations - The investigational ADC telisotuzumab adizutecan (ABBV-400, Temab-A) demonstrated a 63% objective response rate (ORR) in a Phase 1 study involving 41 patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) [3][4]. - ABBV-706, another ADC targeting high-grade neuroendocrine neoplasms (NENs), showed a 31.3% ORR in a Phase 1 study with a median duration of response (DoR) of 5.6 months [4]. - Pivekimab sunirine (PVEK) achieved a 70% composite complete response (CCR) rate in untreated patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA trial [4][5]. Group 2: Ongoing Clinical Trials - Telisotuzumab adizutecan is being evaluated in multiple ongoing trials, including a Phase 1/2 study in first-line NSCLC and a Phase 3 study in refractory metastatic colorectal cancer [3]. - ABBV-706 is under investigation as monotherapy and in combination with other therapies for advanced solid tumors expressing SEZ6 [4]. - Pivekimab sunirine is also being studied in a Phase 1/2 trial for relapsed/refractory acute myeloid leukemia [5]. Group 3: Company Commitment and Strategy - AbbVie emphasizes its commitment to transforming cancer care through targeted therapies and biomarker-driven approaches, reflecting a significant expansion of its ADC portfolio [6][14]. - The company is advancing over 35 investigational medicines across various cancer types, aiming to address unmet medical needs in oncology [15].